Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Current Assets (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Current Assets for 5 consecutive years, with $75.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 44.92% to $75.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $75.7 million through Dec 2025, down 44.92% year-over-year, with the annual reading at $75.7 million for FY2025, 44.92% down from the prior year.
  • Current Assets hit $75.7 million in Q4 2025 for Kezar Life Sciences, down from $94.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $311.3 million in Q2 2022 to a low of $75.7 million in Q4 2025.
  • Historically, Current Assets has averaged $187.3 million across 5 years, with a median of $176.6 million in 2024.
  • Biggest five-year swings in Current Assets: surged 139.62% in 2022 and later plummeted 44.92% in 2025.
  • Year by year, Current Assets stood at $211.7 million in 2021, then surged by 34.99% to $285.7 million in 2022, then fell by 27.57% to $207.0 million in 2023, then plummeted by 33.56% to $137.5 million in 2024, then tumbled by 44.92% to $75.7 million in 2025.
  • Business Quant data shows Current Assets for KZR at $75.7 million in Q4 2025, $94.5 million in Q3 2025, and $104.7 million in Q2 2025.